| |
CBVI |
Staged BVI |
p-value* |
| Follow-up, months median (range) |
25 (7-96) |
30 (7-135) |
0.02 |
| Time between stage I and II (weeks), median (range) |
|
8 (3-116) |
|
| IOP, mmHg |
n mean (sd) |
n mean (sd) |
|
| Preop (stage I for staged BVI) |
67 27.1 (11.9) |
66 21.8 (10.2) |
0.007 |
| Preop (stage II for staged BVI) |
|
66 25.9 (9.5) |
0.52 |
| 1 day |
66 21.0 (12.5) |
64 10.2 ( 7.3) |
<0.001 |
| 1 month |
64 14.4 ( 7.7) |
64 14.5 ( 6.7) |
0.93 |
| 3 months |
63 14.6 ( 7.0) |
62 13.5 ( 5.2) |
0.33 |
| 6 months |
60 13.6 ( 6.2) |
59 13.0 ( 5.1) |
0.58 |
| 1 year |
57 14.2 (10.5) |
57 12.5 ( 3.9) |
0.25 |
| 2 years |
44 14.9 ( 7.2) |
38 14.0 ( 5.1) |
0.50 |
| Glaucoma medications |
n median (range) |
n median (range) |
|
| Preop |
67 3 (0-5) |
66 4 (0-5) |
0.87 |
| 1 day |
67 3 (0-5) |
64 0 (0-5) |
<0.001 |
| 1 month |
65 3 (0-5) |
64 0.5 (0-5) |
<0.001 |
| 3 months |
63 2 (0-5) |
62 1.5 (0-4) |
0.99 |
| 6 months |
63 2 (0-5) |
59 2 (0-4) |
0.80 |
| 1 year |
58 2 (0-4) |
57 2 (0-5) |
0.93 |
| 2 years |
46 1 (0-5) |
37 2 (0-5) |
0.74 |
| Visual acuity |
|
|
0.77 |
| Improved (≥2 Snellen lines) |
19 (28%) |
19 (29%) |
|
| Same (±1 Snellen lines) |
24 (36%) |
20 (30%) |
|
| Worse (≤2 Snellen lines) |
24 (36%) |
27 (41%) |
|
| Life table analysis |
|
|
0.18 |
| Success (12 months) |
72.4% |
81.7% |
|
| Success (24 months) |
67.9% |
79.5% |
|
| *Independent samples t-test and Wilcoxon Rank sum tests for continuous variables, Chi-Square and Fisher’s Exact tests for categorical variables, Log-rank test for life table analysis.
CBVI: Complete BVI; SBVI: Staged (two-stage) BVI |
